14 min listen
Josep M. Llovet, MD, PhD - Enhancing Long-Term Survival in Unresectable HCC: Optimizing First-Line Immunotherapy-Based Combination Regimens
Josep M. Llovet, MD, PhD - Enhancing Long-Term Survival in Unresectable HCC: Optimizing First-Line Immunotherapy-Based Combination Regimens
ratings:
Length:
12 minutes
Released:
Dec 18, 2023
Format:
Podcast episode
Description
Please visit answersincme.com/TAJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hepatocellular carcinoma (HCC) discusses the data for use of first-line immunotherapy-based combination regimens in patients with unresectable HCC. Upon completion of this activity, participants should be better able to: Review the clinical significance of the long-term evidence for immunotherapy-based combination regimens for the first-line treatment of unresectable HCC; Identify patients with unresectable HCC who are appropriate for first-line immunotherapy-based combination regimens; and Outline an individualized, long-term treatment plan that balances the risks and benefits of first-line immunotherapy-based combination regimens for patients with unresectable HCC.
Released:
Dec 18, 2023
Format:
Podcast episode
Titles in the series (88)
Kathleen Moore, MD, MS - Targeting Disease Progression in Advanced Ovarian Cancer: Can Combination PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes?: Please visit answersincme.com/AXF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. by CME in Minutes: Education in Oncology & Hematology